Date: 20 Apr 2007
Cyclooxygenase-2: A novel target in human solid tumors
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The enzyme cyclooxygenase-2, which is involved in the conversion of arachidonic acid-to-prostanoid synthesis, plays a key role in many inflammatory and proliferative reactions. Experimental data have shown that prostaglandins have a central action in therapeutic targeting not only in the treatment of many inflammatory diseases but also in several types of human cancers. Inhibitors of cyclooxygenase activity seem to protect against carcinoma development and show promise as chemopreventive agents and possible target therapies. Data support new treatments for patients with solid cancers tailored to the molecular characteristics of the individual tumor.
References and Recommended Reading
Sano H, Kawahito Y, Wilder RL, et al.: Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995, 55:3785–3789.PubMed
Smith WL: Prostanoid biosynthesis and mechanisms of actions. Am J Physiol 1992, 263:F181–F191.PubMed
Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232–235.PubMed
Bombardier C: An evidence-based evaluation of the gastro-intestinal safety of coxibs. Am J Cardiol 2002, 89S:3D–9D.CrossRef
Norris AE, Jackson RT, McRae C. et al.: Non steroidal anti-inflammatory drug and prostate cancer progression. Int J Cancer 1998, 77:511–515.CrossRef
Howe LR, Subbaramaiah K, Patel J, et al.: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 HER-2)/neu-induced breast cancer. Cancer Res 2002, 62:5405–5407.PubMed
Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993, 122:518–523.PubMed
Eberhart, CE, Coffey RJ, Radhika A, et al.: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 1994, 107:1183–1188.PubMed
Raspollini MR, Amunni G, Villanucci A, et al.: Cyclooxygenase-2 expression in uterine leiomyosarcomas. J Chemother 16:577–581. 2004.PubMed
Denkert C, Kobel M, Pest S, et al.: Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002, 160:893–903.PubMed
Qiao L, Kozoni V, Tsioulias GJ, et al.: Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995, 1258:215–223.PubMed
Sheng HM, Shao JY, Morrow JD, et al.: Modulation of apoptosis and bcl-2 expression by prostaglandins E-2 in human colon cancer cells. Cancer Res 1998, 58:362–366.PubMed
Akhmedkhanov AA, Toniolo P, Zeleniuch-Jacquotte A, et al.: Aspirin and risk of epithelial cancer. Gynecol Oncol 2001, 80:286.
Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al.: Effect of nonsteroidal anti-inflammatory (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002, 8:202–209.PubMed
Nasi ML, Castiglione M: Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled? Ann Oncol 2002, 13:1205–1211.CrossRef
Masunaga R, Kohno H, Dhar DK, et al.: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000, 6:4064–4068.PubMed
Raspollini MR, Amunni G, Villanucci A, et al.: Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression are associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 2005, 15:255–260.PubMedCrossRef
Ratnasinghe D, Daschner PJ, Anver MR, et al.: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance, is chemoprevention against multidrug resistance possible? Anticancer Res 2001, 21:2141–2148.PubMed
Soriano AF, Helfrich B, Chan DC, et al.: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999, 59:6178–6184.PubMed
Hida T, Kozaki K, Muramatsu H, et al.: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000, 6:2006–2011.PubMed
DiSaia PJ, Bloss JD: Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003, S24–S32.
Mrozek E, Kloos RT, Ringel MD, et al.: Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metabol 2006, 91:2201–2204.CrossRef
Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000, 6:135–138.PubMed
Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:705–716.CrossRef
Kakiuki Y, Tsujii S, Tsujii M: Cyclooxygenase-2 activity altered the cell-surface in colon cancer cells and enhanced liver metastasis. Cancer Res 2002, 62:1567–1572.
- Cyclooxygenase-2: A novel target in human solid tumors
Current Oncology Reports
Volume 9, Issue 2 , pp 96-101
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links